Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.6.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jan. 31, 2017
Jan. 31, 2016
Jan. 31, 2017
Jan. 31, 2016
Revenues:        
Clinical laboratory services $ 18,837 $ 17,523 $ 37,395 $ 34,613
Product revenues 6,983 6,578 14,409 14,265
Royalty and license fee income 440 459 740 859
Total revenues 26,260 24,560 52,544 49,737
Operating costs, expenses and legal settlements, net:        
Cost of clinical laboratory services 11,052 10,535 21,948 20,867
Cost of product revenues 3,520 3,206 6,829 6,817
Research and development 483 861 1,305 1,728
Selling, general and administrative 11,165 11,280 22,639 21,505
Provision for uncollectible accounts receivable 679 459 1,348 1,163
Legal fee expense 370 2,411 742 4,012
Legal settlements, net   (11,650)   (18,450)
Total operating costs, expenses and legal settlements, net 27,269 17,102 54,811 37,642
Operating income (loss) (1,009) 7,458 (2,267) 12,095
Other income (expense):        
Interest 79 (42) 125 (82)
Other 24 11 143 65
Foreign exchange loss (94) (388) (455) (518)
Income (loss) before income taxes (1,000) 7,039 (2,454) 11,560
Provision for income taxes (53) (207) (73) (294)
Net income (loss) $ (1,053) $ 6,832 $ (2,527) $ 11,266
Net income (loss) per common share:        
Basic (in Dollars per share) $ (0.02) $ 0.15 $ (0.05) $ 0.24
Diluted (in Dollars per share) $ (0.02) $ 0.15 $ (0.05) $ 0.24
Weighted average common shares outstanding:        
Basic (in Shares) 46,292 46,077 46,282 46,070
Diluted (in Shares) 46,292 46,518 46,282 46,353